全球基础设施ETF-iShares IGF 深 沪
已收盘 10-03 16:00:00 美东时间
61.61
+0.370
+0.60%
华盛通- 最 高61.86
- 今 开61.35
- 成交量 67.02万股
- 最 低 61.30
- 昨 收 61.24
- 总市值 75.78亿
- 52周最高 61.86
- 市盈率 静 --
- 换手率 0.54%
- 52周最低 48.7566
- 委 比 0.00%
- 总股本 1.23亿
- 历史最高 61.86
- 量 比 1.06
- 振 幅 0.91%
- 历史最低 19.4519
- 每 手 1
- 风险率 3.44%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Crinetics Pharmaceuticals Receives FDA Approval For PALSONIFY; PALSONIFY Is Expected To Be Available In The U.S. In Early October
SAN DIEGO, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) today announced that the U.S.
09-26 05:33
Denmark plans long-range weapons purchase to counter Russia
Denmark will acquire long-range precision weapons as part of a broader military buildup prompted by Russia’s war in Ukraine, Prime Minister Mette Frederiksen said Wednesday, according to several press...
09-17 22:16
长春高新：公司长效生长激素经长期安全验证，国内唯一
8月31日，长春高新（000661.SZ）在电话会议中表示，目前，子公司金赛药业已拥有重组人促卵泡激素粉剂及水剂产品，预计今年一周注射一次的长效FSH水剂可以获...
09-01 14:27
BlackRock's New ETF BILT Bets On $68 Trillion Boom, But Most Investors Are Missing It
BlackRock debuts first actively managed infrastructure ETF (BILT), highlighting growing interest in this sector. Offers diversity and growth potential.
08-01 07:04
Barclays Remains a Sell on Nexans (0IGF)
Barclays analyst Xin Wang, CFA maintained a Sell rating on Nexans today and set...
07-31 17:56
Purple Biotech's Chief Executive Officer Gil Efron Issued A Letter To Shareholders Highlighting The Company's Scientific Progress, Operational Execution, And Strategic Milestones During 1H 2025
2025 First Half HighlightsCM24 (α-CEACAM1 monoclonal antibody)Our Phase 2 dataset demonstrated strong objective response rates (ORR) in biomarker-enriched subgroups of second line PDAC patients, as outlined below. These
07-24 19:29
Reported Sunday, Crinetics Highlights Interim Data from PATHFNDR-1 And PATHFNDR-2 Extensions Confirming Long-Term Efficacy And Tolerability of PALSONIFY In Acromegaly
Data show that PALSONIFY was well tolerated and IGF-1 levels remained stably controlled during long-term open label extensions of PATHFNDR-1 and PATHFNDR-2 studiesAdditional PALSONIFY presentations demonstrate reductions
07-14 14:44
